Please login to the form below

Not currently logged in

Strong Tagrisso soothes AZ as US sales plummet

Sales decline 34% in the US due to low-cost copies of Crestor


Strong sales of new lung cancer drug Tagrisso proved a balm to AstraZeneca in the first quarter, as generic competition cut away a third of its US sales.

Buoyant uptake for Tagrisso (osimertinib) in the US and EU saw the drug reach $171m in sales, up from $51m a year ago, to become AZ's third-biggest cancer drug.

Tagrisso has just recently seen its conditional approvals in the US and EU for second-line non-small cell lung cancer (NSCLC) treatment converted to full approval, and is due to get a read-out in its first-line NSCLC trial later this year - which analysts suggest could help drive sales to around $2bn a year. It also picked up new second-line approvals in Brazil, Hong Kong and Taiwan during the first quarter.

AZ needs Tagrisso and other growth-phase drugs such as ovarian cancer therapy Lynparza (olaparib) - which rose 30% to $57m in the quarter - to help offset dramatic declines in mature products that have lost patent protection. That impact was felt particularly strongly in the US, where sales declined 34% to $1.49bn thanks largely to the launch of low-cost copies of cholesterol drug Crestor (rosuvastatin) in the latter half of 2016.

Overall, AZ reported a 12% decrease in group revenues to $5.4bn in the first quarter, which was in line with analyst expectations, and the company said it is confident that the big year-on-year declines will start to recede in the second half of this year and into 2018.

AZ has been selling off older and non-core assets left and right as it pushes the accelerator on its R&D pipeline, and says it is entering a particularly productive period that could see six new drugs launched for cancer alone between 2014 and 2020 - including Lynparza and Tagrisso.

AZ is playing catch-up in the immuno-oncology sector, but lead candidate durvalumab - a PD-L1 inhibitor - is under regulatory review as a second-line therapy for patients with locally-advanced or metastatic urothelial carcinoma (mUC), with an FDA verdict due in the second quarter of this year.

It is also expecting phase III results from a combination trial of durvalumab with CTLA-4 inhibitor tremelimumab in third-line NSCLC in the second half of the year, with data readout from a first line combination trial due in 2018. Results from a study of durvalumab plus tremelimumab in first-line head and neck cancer are also expected before the end of 2017.

Meanwhile in its targeted oncology portfolio AZ is also expecting to file BTK inhibitor acalabrutinib for B-cell malignancies later this year, with MEK inhibitor selumetinib for thyroid cancer and   moxetumomab pasudotox for hairy cell leukaemia due for first regulatory submissions in 2018.

Commenting on the first-quarter performance, AZ's chief executive Pascal Soriot said: "The pipeline continued to deliver in what we expect will be a pivotal year for AZ as we announced important developments, in particular in oncology."

"Importantly, we anticipate the significant progress of the pipeline to continue, including our immuno-oncology and targeted treatments," he added.

Article by
Phil Taylor

28th April 2017

From: Sales



COVID-19 Updates and Daily News

Featured jobs


Add my company
Mednet Group

Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...

Latest intelligence

The disparity of patient experiences with Crohn’s Disease in Europe and Japan...
Patient diversity in clinical trials
The pursuit of patient diversity in clinical trials
When all-inclusive isn’t an option, it’s an obligation...
Overcoming the digital patient recruitment challenges of connecting with patients
How many irrelevant experiences, ads, emails, direct messages have you rejected this week?...